Abstract
Standard triple therapy for Helicobacter pylori infection — omeprazole, amoxicillin, and clarithromycin (OAC) — is increasingly unsuccessful in some regions of the world because of antibiotic resistance. The European Consensus Report recommends bismuth-based quadruple therapy (BBT; bismuth subcitrate, metronidazole, and tetracycline, plus a proton-pump inhibitor) as first-line treatment in regions with high rates of clarithromycin resistance, but its …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
